Background
Treatment of in-stent restenosis of the femoropopliteal vessels with balloon angioplasty carries a high rate of recurrence and repeat stenting. Silverhawk atherectomy (SA) has a theoretical advantage of reducing the volume of restenotic tissue and delaying the need for repeat revascularization and stenting. We present a retrospective analysis from our center on the use of SA in treating in-stent restenosis and report on its safety and rates of one-year target lesion revascularization (TLR) and target vessel revascularization (TVR).
Methods
Demographic, clinical, angiographic, and procedural data were collected on all patients that underwent SA for in-stent restenosis from January 2005 until June 2010. Major adverse events and one-year TLR and TVR were obtained by the review of medical records. Descriptive analysis was performed on all variables.
Methods
Demographic, clinical, angiographic, and procedural data were collected on all patients that underwent SA for in-stent restenosis from January 2005 until June 2010. Major adverse events and one-year TLR and TVR were obtained by the review of medical records. Descriptive analysis was performed on all variables.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
